Pharma BD Deal Intelligence
Inhale paid ~$200M in cash and stock for Bradford Particle Design's supercritical-fluid particle-engineering technology, then shut the entire UK site under five years later, stating the technology wasn't a fit for its strategy. One inhaled migraine asset was licensed out to MAP Pharmaceuticals rather than developed in-house, and former staff spun out Crystec to continue the IP independently.
Inhale paid ~$200M in cash and stock for Bradford's supercritical-fluid particle technology, then shut the entire UK site five years later, publicly stating the tech didn't fit its strategy — one licensed spinout asset aside, the acquisition was effectively abandoned.
Full analysis, sources & comparables →Inhale Therapeutic Systems offered $20M cash plus 3.75M shares (~$200M total) for Bradford Particle Design, calling SEDS the leading supercritical-fluid…
The University of Bradford will be £36 million richer today after selling its share of spin-off Bradford Particle Design to Inhale for £200 million in cash and…
BPD was acquired by Inhale Therapeutic Systems in January 2001; the SEDS platform was widely regarded as the industry's leader in supercritical-fluid particle…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
$20M cash plus 3.75M Inhale shares (~$200M total). Supercritical-fluid particle engineering; pulmonary drug delivery.
Inhale paid ~$200M in cash and stock for Bradford's supercritical-fluid particle technology, then shut the entire UK site five years later, publicly stating the tech didn't fit its strategy — one licensed spinout asset aside, the acquisition was effectively abandoned.
Assessment window: 15yr post-close.
Pulmonary drug delivery uses the lung as a route of administration for systemic and local therapeutics, enabling needle-free dosing of macromolecules (insulin, peptides, proteins) and small molecules. Particle engineering — controlling size, morphology, and density of dry-powder formulations — is the central technical challenge for achieving reproducible deep-lung deposition.
In 2001, the inhalable drug delivery field was a three-way race between Inhale Therapeutic Systems (Pfizer-partnered insulin program that became Exubera), Aradigm (AERx liquid platform with Novo Nordisk), and Alkermes (AIR large-porous-particle technology with Eli Lilly). Bradford Particle Design's SEDS (Solution Enhanced Dispersion by Supercritical fluids) technology was widely regarded as the industry leader in supercritical-fluid particle engineering and offered a route to controlled, narrow-distribution dry powders without the milling losses of conventional methods. Acquiring BPD gave Inhale a defensible IP moat in particle engineering on top of its existing dry-powder formulation and device platform, and set up the 2003 fusion of Inhale + Shearwater + BPD that rebranded as Nektar Therapeutics. The deal mattered because the inhalable insulin opportunity (Exubera) hinged on consistent particle performance — and competitors lacked supercritical fluid IP. Exubera was ultimately approved by FDA in 2006 but withdrawn by Pfizer in 2007 due to poor uptake, blunting the strategic payoff.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Inhale Therapeutic Systems Inc. / Bradford Particle Design plc (UK) (this deal) | 2001 | $200M | 14 |
| Inhale Therapeutic Systems Inc. / Shearwater Corporation | 2001 | $192M | 73 |
| Abbott Laboratories / Knoll Pharmaceutical Company (BASF Pharma) | 2001 | $6.9B | 100 |
| Vertex Pharmaceuticals Incorporated / Aurora Biosciences Corporation | 2001 | $592M | 95 |
| Amgen Inc. / Immunex Corporation | 2001 | $16.0B | 91 |
| Swedish Orphan Biovitrum AB / Biovitrum | 2001 | $493M | 84 |
| Barr Laboratories Inc. / Duramed Pharmaceuticals Inc. | 2001 | $589M | 82 |
← Browse all deals · How we score deals
More: 2001 deals